Institutions / Tang Capital Management, LLC
Tang Capital Management, LLC
CIK 1232621 · Institution · as of Mar 31, 2026
Portfolio value
$1.97B
Positions
51
As of
Mar 31, 2026
Portfolio trend
Portfolio value
$1.97B-2.7%Positions
51-32.0%Top holdings
Mar 31, 2026View all 51 →
| Company | Value | % of portfolio |
|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH | $181.24M | 9.2% |
| Celcuity Inc.CELC | $119.85M | 6.1% |
| Mirum Pharmaceuticals, Inc. | $114.18M | 5.8% |
| Galapagos NV | $113.58M | 5.8% |
| State Str SPDR S&P 500 ETF T | $109.26M | 5.5% |
| Kiniksa Pharmaceuticals International, plc | $108.81M | 5.5% |
| Capricor Therapeutics, Inc. | $103.36M | 5.2% |
| PTC Therapeutics Inc | $102.19M | 5.2% |
| Spyre Therapeutics, Inc. | $95.44M | 4.8% |
| KalVista Pharmaceuticals Inc | $92.07M | 4.7% |
| Compass Therapeutics, Inc. | $88.82M | 4.5% |
| Tarsus Pharmaceuticals, Inc. | $83.38M | 4.2% |
| Immunocore Holdings Plc-AdrIMCR | $79.88M | 4.1% |
| AnaptysBio, Inc. | $73.81M | 3.7% |
| Corcept Therapeutics Inc | $60.47M | 3.1% |
| Ani Pharmaceuticals Inc | $54.41M | 2.8% |
| Insmed Inc | $42.52M | 2.2% |
| BioNTech SEBNTX | $41.77M | 2.1% |
| Viridian Therapeutics, Inc. | $35.06M | 1.8% |
| Atea Pharmaceuticals, Inc. | $25.90M | 1.3% |
| Precigen, Inc. | $24.84M | 1.3% |
| Dianthus Therapeutics, Inc. | $22.21M | 1.1% |
| COMPASS Pathways plcCMPS | $22.13M | 1.1% |
| Crescent Biopharma, Inc. | $21.31M | 1.1% |
| Stoke Therapeutics, Inc. | $16.28M | 0.8% |
Activity
Mar 31, 2026View full history →
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q1 2026 as of | Add | 78462F103 | $89.75M | +138K +460.00% | 168,000 5.55% of portfolio | high |
| Q1 2026 as of | Exit | Avidity Biosciences, Inc. | $-64.92M | -900K -100.00% | — | high |
| Q1 2026 as of | Add | Corcept Therapeutics Inc | $54.15M | +1.3M +856.85% | 1,500,000 3.07% of portfolio | high |
| Q1 2026 as of | Add | Capricor Therapeutics, Inc. | $51.68M | +1.7M +99.99% | 3,399,900 5.25% of portfolio | high |
| Q1 2026 as of | Exit | Vertex Pharmaceuticals Inc / Ma | $-36.27M | -80K -100.00% | — | medium |
| Q1 2026 as of | Add | Insmed Inc | $32.70M | +200K +333.33% | 260,000 2.16% of portfolio | medium |
| Q1 2026 as of | Trim | Moderna, Inc. | $-30.12M | -593K -85.57% | 100,000 0.26% of portfolio | medium |
| Q1 2026 as of | Exit | Travere Therapeutics, Inc. | $-26.75M | -700K -100.00% | — | medium |
| Q1 2026 as of | Exit | Ventyx Biosciences, Inc. | $-25.41M | -2.8M -100.00% | — | medium |
| Q1 2026 as of | Exit | NVIDIA Corp | $-23.83M | -128K -100.00% | — | medium |